We can only change patient’s lives when we perform at our best together. This happens when we focus on what matters, agree who does what and measure our outcomes.
Breakthroughs start by challenging convention, especially in the face of uncertainty or adversity. This happens when we think big, speak up and are decisive.
We believe that every person deserves to be seen, heard and cared for. This happens when we are inclusive, act with integrity and reduce health care disparities.
We give ourselves to our work, but it also gives to us. We find joy when we take pride, recognize one another and have fun.
Watch for a glimpse into the lives of Pfizer scientists as they work to help end the
COVID-19 pandemic and reflect on the personal impact of their work.
We’re ready for another 170 years of breakthroughs
But first, a look at where we’ve been as we take a look to our future.
Watch how our history of breakthrough science has led us to this moment.
Connecting our purpose, strategy and ESG
Our new approach to ESG helps us to advance on our purpose, drive positive impact relevant to the breakthroughs we aim to deliver, demonstrate the value they bring to patients and other stakeholders and govern our operations and impact on society.
Pfizer has consistently supported and prioritized its ESG-related programs and commitments. 2020 marked an important inflection point when it comes to the role of corporations in society, and I am very proud of the ways in which Pfizer stepped up to lead.”
Dr. Albert Bourla
Chairman and Chief Executive Officer
A closer look: ESG at Pfizer
Building on our commitment to environmental impact reduction through successful completion of our 2012 – 2020 Greenhouse Gas, waste and water withdrawal reduction goals, we are renewing our commitment to ambitious climate action. Our goal is to become carbon neutral across our internal operations by 2030 and catalyze similar reductions throughout our value chain, as recognized by the Science Based Target Initiative. We further aim to reduce the environmental impact of our medicines throughout the product lifecycle through the development of sustainability criteria to measure our progress.
As we work to meet patient and societal needs, we are committed to acting ethically, thoughtfully and responsibly and continually prioritizing safety and transparency in all that we do. Our compliance program supports proactive business-led quality and compliance governance built around elements of effective risk management. The Board of Directors is critical to our governance by representing shareholders’ interests and seeking to enhance long-term shareholder value. The Board is composed of a majority of independent Directors, reflecting diversity with respect to gender, age, race, ethnicity, background, professional experience and perspectives.
Our Environmental, Social and Governance (ESG) report represents a new chapter in Pfizer’s commitment to enhance stakeholder awareness of our priority ESG issues and disclose how our performance on non-financial metrics is contributing to long-term value creation and a sustainable, responsible and patient-centric business model.
Download the report
Chairman and CEO Albert Bourla reflects on a year of breakthrough innovation at Pfizer
Science illuminates a path forward for patients across the world
Courage, excellence, equity and joy guide all our endeavors
2020 by the numbers
Read the latest information about Pfizer’s COVID-19 vaccine on Pfizer.com.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.
Copyright © 2020-2021 Pfizer Inc.
All rights reserved